MA43861A - Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie - Google Patents
Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapieInfo
- Publication number
- MA43861A MA43861A MA043861A MA43861A MA43861A MA 43861 A MA43861 A MA 43861A MA 043861 A MA043861 A MA 043861A MA 43861 A MA43861 A MA 43861A MA 43861 A MA43861 A MA 43861A
- Authority
- MA
- Morocco
- Prior art keywords
- chemotherapy
- inhibitors
- treatment
- peripheral neuropathy
- induced peripheral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151618.2A EP3192504A1 (en) | 2016-01-15 | 2016-01-15 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| EP16190871 | 2016-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43861A true MA43861A (fr) | 2021-05-05 |
Family
ID=57906595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043861A MA43861A (fr) | 2016-01-15 | 2017-01-13 | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12268671B2 (enExample) |
| EP (1) | EP3402474B1 (enExample) |
| JP (1) | JP7049254B2 (enExample) |
| KR (1) | KR102737378B1 (enExample) |
| CN (1) | CN108463219B (enExample) |
| AU (1) | AU2017207850B2 (enExample) |
| CA (1) | CA3009438A1 (enExample) |
| CY (1) | CY1125297T1 (enExample) |
| DK (1) | DK3402474T3 (enExample) |
| ES (1) | ES2893701T3 (enExample) |
| HR (1) | HRP20211527T1 (enExample) |
| HU (1) | HUE056606T2 (enExample) |
| IL (1) | IL260373B (enExample) |
| LT (1) | LT3402474T (enExample) |
| MA (1) | MA43861A (enExample) |
| MX (1) | MX388815B (enExample) |
| PL (1) | PL3402474T3 (enExample) |
| RS (1) | RS62427B1 (enExample) |
| SG (1) | SG11201804484YA (enExample) |
| SI (1) | SI3402474T1 (enExample) |
| SM (1) | SMT202100571T1 (enExample) |
| WO (1) | WO2017121838A1 (enExample) |
| ZA (1) | ZA201803486B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101914358B1 (ko) * | 2017-01-18 | 2018-11-02 | 현대로템 주식회사 | 실내등 제어회로 및 이를 포함하는 철도차량 |
| CN111343973A (zh) * | 2017-10-24 | 2020-06-26 | 多姆皮制药公司 | 用于治疗一些肉瘤的il-8抑制剂 |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
| IL302553A (en) * | 2020-11-05 | 2023-07-01 | Icahn School Med Mount Sinai | Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis |
| EP4397305A1 (en) * | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (it) | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| DE602005016937D1 (de) | 2004-03-23 | 2009-11-12 | Dompe Pha R Ma Spa Res & Mfg | Pharmazeutische zusammensetzung |
| WO2008039876A1 (en) | 2006-09-26 | 2008-04-03 | Case Western Reserve University | Cytokine signaling |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| CR20160557A (es) | 2014-05-29 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 |
| EP3174851A1 (en) | 2014-07-31 | 2017-06-07 | GlaxoSmithKline Intellectual Property Management Limited | Use of cxcr2 antagonists for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn) |
-
2017
- 2017-01-13 JP JP2018537469A patent/JP7049254B2/ja active Active
- 2017-01-13 WO PCT/EP2017/050637 patent/WO2017121838A1/en not_active Ceased
- 2017-01-13 ES ES17701646T patent/ES2893701T3/es active Active
- 2017-01-13 MX MX2018008614A patent/MX388815B/es unknown
- 2017-01-13 LT LTEPPCT/EP2017/050637T patent/LT3402474T/lt unknown
- 2017-01-13 CN CN201780005946.9A patent/CN108463219B/zh active Active
- 2017-01-13 DK DK17701646.6T patent/DK3402474T3/da active
- 2017-01-13 CA CA3009438A patent/CA3009438A1/en active Pending
- 2017-01-13 HU HUE17701646A patent/HUE056606T2/hu unknown
- 2017-01-13 US US16/066,072 patent/US12268671B2/en active Active
- 2017-01-13 AU AU2017207850A patent/AU2017207850B2/en active Active
- 2017-01-13 SM SM20210571T patent/SMT202100571T1/it unknown
- 2017-01-13 HR HRP20211527TT patent/HRP20211527T1/hr unknown
- 2017-01-13 KR KR1020187019923A patent/KR102737378B1/ko active Active
- 2017-01-13 EP EP17701646.6A patent/EP3402474B1/en active Active
- 2017-01-13 PL PL17701646T patent/PL3402474T3/pl unknown
- 2017-01-13 MA MA043861A patent/MA43861A/fr unknown
- 2017-01-13 SG SG11201804484YA patent/SG11201804484YA/en unknown
- 2017-01-13 SI SI201730924T patent/SI3402474T1/sl unknown
- 2017-01-13 RS RS20211209A patent/RS62427B1/sr unknown
-
2018
- 2018-05-25 ZA ZA2018/03486A patent/ZA201803486B/en unknown
- 2018-07-02 IL IL260373A patent/IL260373B/en active IP Right Grant
-
2021
- 2021-10-14 CY CY20211100886T patent/CY1125297T1/el unknown
-
2025
- 2025-02-27 US US19/064,835 patent/US20250195479A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102737378B1 (ko) | 2024-12-04 |
| SI3402474T1 (sl) | 2021-12-31 |
| HUE056606T2 (hu) | 2022-02-28 |
| LT3402474T (lt) | 2021-11-25 |
| AU2017207850B2 (en) | 2022-06-30 |
| DK3402474T3 (da) | 2021-10-11 |
| PL3402474T3 (pl) | 2021-12-27 |
| AU2017207850A1 (en) | 2018-06-21 |
| ZA201803486B (en) | 2019-09-25 |
| CN108463219A (zh) | 2018-08-28 |
| EP3402474B1 (en) | 2021-07-21 |
| SG11201804484YA (en) | 2018-07-30 |
| US12268671B2 (en) | 2025-04-08 |
| EP3402474A1 (en) | 2018-11-21 |
| KR20180101390A (ko) | 2018-09-12 |
| JP7049254B2 (ja) | 2022-04-06 |
| WO2017121838A1 (en) | 2017-07-20 |
| IL260373B (en) | 2021-03-25 |
| RS62427B1 (sr) | 2021-11-30 |
| CA3009438A1 (en) | 2017-07-20 |
| CY1125297T1 (el) | 2023-03-24 |
| US20190015391A1 (en) | 2019-01-17 |
| ES2893701T3 (es) | 2022-02-09 |
| BR112018013570A2 (pt) | 2018-12-11 |
| CN108463219B (zh) | 2021-09-17 |
| SMT202100571T1 (it) | 2021-11-12 |
| MX388815B (es) | 2025-03-20 |
| MX2018008614A (es) | 2018-11-19 |
| JP2019501948A (ja) | 2019-01-24 |
| US20250195479A1 (en) | 2025-06-19 |
| HRP20211527T1 (hr) | 2021-12-24 |
| NZ743344A (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3706755A4 (en) | GANAXOLONE FOR USE IN THE TREATMENT OF GENETIC EPILEPTIC DISEASES | |
| EP3631846A4 (en) | ELECTROSTATIC CHUCK FOR USE IN SEMICONDUCTOR PROCESSING | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| EP3455205A4 (en) | PEPTIDOMIMETICS FOR TREATING A NOVOVIRUS INFECTION | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| MA50155A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA44676A (fr) | Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius | |
| MA54290A (fr) | Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome | |
| MA45073A (fr) | Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers | |
| EP3452060A4 (en) | Combination therapy for cancer treatment | |
| EP3558313A4 (en) | SUBSTANCES FOR TREATING CONDITIONS RELATING TO FATTY LIVER | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| EP3405183A4 (en) | ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| EP3503904A4 (en) | ASCAROSIDE TREATMENT OF EOSINOPHILER OESOPHAGITIS | |
| EP3430400A4 (en) | DOSAGE PLANS FOR THE TREATMENT OF FUNGI INFECTIONS | |
| EP3641888A4 (en) | PLASMINOGEN TREATMENT OF DISEASES RELATED TO PAI-1 OVEREXPRESSION | |
| EP3496743A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ARGININE DEPLETION AND IMMUNOLOGICAL ACTIVE SUBSTANCES | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| EP3813870C0 (en) | CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | |
| EP3806679A4 (en) | CAPSULES FOR USE IN PERSONAL VAPORIZERS | |
| MA51978A (fr) | Phénytoïne à usage topique destinée a être utilisée dans le traitement de la douleur neuropathique périphérique |